Robert Stagg

Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas

Mark Kaminski, Andrew D. Zelenetz, Oliver W. Press et al. · Journal of Clinical Oncology · 2001 · 586 citations

Medicine, Oncology, Pharmacology +15

Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience

Mark Kaminski, Judith Estes, Kenneth Zasadny et al. · Blood · 2000 · 521 citations

Medicine, Nuclear Medicine, Oncology +14

A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial.

David C. Hohn, Robert Stagg, Michael Friedman et al. · Journal of Clinical Oncology · 1989 · 455 citations

Medicine, Oncology, Pharmacology +17

Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas

Julie M. Vose, Richard L. Wahl, Mansoor N. Saleh et al. · Journal of Clinical Oncology · 2000 · 362 citations

Medicine, Hematology, Oncology +14

A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors

Antonio Jimeno, Michael A. Gordon, Rashmi Chugh et al. · Clinical Cancer Research · 2017 · 204 citations

Medicine, Oncology, Pharmacology +17